Study guide

6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements

Key Takeaways Explain This Topic AI

Oregon pharmacists prescribing under the formulary or a protocol must notify the patient's primary care provider within five business days and keep records for seven years.

An Oregon pharmacist may not prescribe under the formulary or a protocol to themselves, or when the protocol requires referral (OAR 855-115-0335).

Oregon formulary items such as diabetic supplies, CGMs, spacers and epinephrine are prescribed pursuant to a qualified practitioner's diagnosis, with the diagnosis code documented.

As of October 2026, Oregon's protocols cover continuation of therapy, cough and cold, COVID-19, contraception, emergency contraception, tobacco, travel, PrEP/PEP, STI PEP, naloxone, MOUD and vaccines.

ORS 689.704 lets Oregon pharmacists prescribe HIV PrEP, including up to a 30-day supply based solely on the pharmacist's reading of a negative HIV test.

Last updated: October 2026

Why this matters

Oregon gives pharmacists unusually broad independent prescribing authority through a formulary and a set of statewide drug therapy management protocols . These are recommended by the Public Health and Pharmacy Formulary Advisory Committee (PHPFAC) and adopted by the Board (ORS 689.645 and 689.649). The MPJE tests which products are covered, the general conditions for any pharmacist prescribing, and the documentation and notification duties.

General conditions for all formulary and protocol prescribing (OAR 855-115-0330)

A pharmacist licensed and located in Oregon may prescribe an FDA-approved drug or device under the formulary or a protocol only if they:

Complete any required training first and keep proof (six years under OAR 855-104-0055, or uploaded to eGov).

Follow the protocol's standardized assessment and care pathway. Required physical assessments must happen in a face-to-face, in-person interaction.

Create an individualized, patient-centered care plan and monitor its effectiveness.

Provide notification to the patient's identified primary care provider or other care providers, when applicable, within five business days of prescribing.

Document the encounter and keep prescribing records for seven years .

The prohibitions in OAR 855-115-0335 are tested as well. A pharmacist may not prescribe under the formulary or a protocol to themselves , or when the formulary or protocol requires referral to a non-pharmacist provider. For hormonal contraception, a pharmacist may not require an appointment, though one may be allowed.

The formulary (OAR 855-115-0340)

The formulary covers post-diagnostic drugs and devices. The pharmacist prescribes them pursuant to a diagnosis made by a qualified practitioner and documents the diagnosis code . The current formulary covers:

Diabetic blood glucose testing supplies and continuous glucose monitors .

Injection supplies, nebulizers and supplies, inhalation spacers and peak flow meters .

INR testing supplies, enteral nutrition supplies and ostomy supplies.

Non-invasive blood pressure monitors.

Epinephrine , added effective January 23, 2026.

The protocol compendium (OAR 855-115-0345)

Protocols are assessment-based : the pharmacist follows the Board's standardized intake form and care pathway. As of October 2026 the compendium included:

Category Protocols

Continuation of therapy Continuation of therapy, including emergency refills of insulin and early refills of opioid use disorder medications (see section 8.4)

Conditions Cough and cold symptom management (benzonatate, intranasal corticosteroid, short-acting beta-agonist); COVID-19 antigen self-testing; SARS-CoV-2 antivirals

Preventive care Contraception; emergency contraception; condoms; tobacco cessation; travel medications; HIV pre-exposure (PrEP) and post-exposure (PEP) prophylaxis; sexually transmitted infection PEP; short-acting opioid antagonists

Opioid use disorder Medications for opioid use disorder (MOUD): initiation of therapy, and continuation or modification of therapy

Vaccines Standard protocols for adults 18 and older and for persons 7 through 17; managing adverse reactions; separate COVID-19, influenza and respiratory syncytial virus (RSV) protocols

There is no statewide influenza or group A strep test-and-treat protocol. ORS 689.645(6)(b) lists rapid strep tests among items the formulary may include, and ORS 689.662 authorizes COVID-19 test-and-treat. A pharmacist may prescribe only what the Board has actually adopted, and the current formulary does not include strep testing.

HIV PrEP and PEP (ORS 689.704)

A pharmacist may prescribe, dispense and administer HIV PrEP , and PEP under Board rules. The pharmacist may perform an HIV test or order one from a laboratory, complying with ORS 433.045. The rules must allow up to a 30-day supply of PrEP based solely on the pharmacist's reading of an HIV-negative test.

COVID-19 (ORS 689.662)

A pharmacist may test for SARS-CoV-2 using a CLIA-waived or FDA-approved test the Board approves. They may then prescribe, dispense and administer treatment under the protocols, and may delegate the technical testing tasks to a supervised technician or intern.

Travel medications and cough/cold

These protocols use standardized assessments, with references to CDC Yellow Book travel guidance and Board care pathways. As with every protocol, a finding outside the pathway, such as red-flag symptoms, requires referral.

How the Board keeps the compendium current

The Board adopts each protocol by version date . It often uses temporary rules when federal guidance changes, as it did for several 2025–2026 vaccine protocols, followed by permanent rules. Pharmacists may submit protocol concepts or formulary additions to the PHPFAC on Board forms (ORS 689.645(1)(c); ORS 689.649(8)). Pharmacies document their prescribing services on the annual self-inspection form.

Tip

When an exam item asks whether a pharmacist may "prescribe X," check three things. Is X on the formulary (with a diagnosis), or covered by an adopted protocol (with an assessment)? Does a statute authorize it, as with contraception, insulin, PrEP/PEP, MOUD or naloxone? Is anything prohibited , such as self-prescribing or a required referral?

Exam scenario

A patient with a physician diagnosis of type 2 diabetes asks an Oregon pharmacist for a continuous glucose monitor because their prescription lapsed. CGMs are on the formulary , so the pharmacist may prescribe one pursuant to the documented diagnosis , recording the diagnosis code. The pharmacist notifies the patient's primary care provider within five business days and keeps the record for seven years . If the same patient asked for metformin, the formulary would not apply. The pharmacist would look to the continuation-of-therapy protocol, which needs evidence of a previous prescription.